According to the Rotterdam PCOS criteria, the prevalence of PCOS in India is 22.5%. At present, combined oral contraceptive (COC) is an effective method for the treatment of PCOS. The limitations of 2^nd and 3^rd generation COC are that they have side effects like acne and weight gain. Use of fourth-generation COC containing ethinylestradiol (EE) together with a novel progestin, drospirenone (DRSP), have claimed to have properties closer to those of natural progesterone, including anti-mineralocorticoid and anti-androgenic activities and thereby, decrease in acne formation. Vitamin E, which is critically important in the whole process of reproduction, can antagonize the oxidative stress caused by the oxygen free radicals and antioxidant imbalance and regulate normal physiological function of the reproductive system. Subjects who are diagnosed with polycystic ovarian syndrome (PCOS) according to Rotterdam criteria will be recruited. Informed consent will be obtained from all the participants. Randomization will be done in three groups by computer generated software program. Group 1 (DRSP) will be administered with 4^th generation combined oral contraceptives (COC) that is drospirenone 3mg with ethinyl estradiol 20 mcg orally once daily before bedtime for 28 days: 24consecutive days with 4 days placebo tablets days (1 cycle) for period of 3 months. Group 2 (DRSP+ E2) will be administered with 4^th generation combined oral contraceptives (COC) that is drosperinone 3mg with ethinyl estradiol 20 mcg orally once daily before bedtime for 28 days: 24 consecutive days with 4 days placebo tablets days (1 cycle) and vitamin E200mg once daily for the period of 3 months. Group 3 (DRSP+ E4) will be administered with 4^th generation combined oral contraceptives (COC) that is drosperinone 3mg with ethinyl estradiol 20 mcg orally once daily before bedtime for 28 days: 24 consecutive days with 4 days placebo tablets days (1 cycle) and vitamin E 400mg once daily for the period of 3 months. Group 4 (Adolescent) will be administered with vitamin E 400mg once daily for the period of 3 months. All the demographic characteristics and baseline parameters will be recorded. Total testosterone, and follicle stimulating hormone (FSH) and insulin resistance will be examined in 2 months and 3 months. In Oxidative stress, Total Antioxidant Capacity (TAC) will be measured by colorimetric assay at absorbance 570nm, and Glutathione (GSH) will be measured by colorimeter at absorbance 412 nm will be measured by HPLC. All oxidative stress parameters will be determined after 3 months.